Form 8-K - Current report:
SEC Accession No. 0000950170-25-102027
Filing Date
2025-08-04
Accepted
2025-08-04 16:21:40
Documents
11
Period of Report
2025-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crsp-20250804.htm   iXBRL 8-K 54429
2 EX-99.1 crsp-ex99_1.htm EX-99.1 242538
  Complete submission text file 0000950170-25-102027.txt   420432

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20250804.xsd EX-101.SCH 25983
13 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20250804_htm.xml XML 4500
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37923 | Film No.: 251180570
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)